Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Genital Herpes Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Genital Herpes Overview | 11 | 1 |
| Pipeline Products for Genital Herpes Comparative Analysis | 12 | 1 |
| Genital Herpes Therapeutics under Development by Companies | 13 | 2 |
| Genital Herpes Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Genital Herpes Pipeline Products Glance | 16 | 2 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Genital Herpes Products under Development by Companies | 18 | 1 |
| Genital Herpes Products under Investigation by Universities/Institutes | 19 | 1 |
| Genital Herpes Companies Involved in Therapeutics Development | 20 | 21 |
| Admedus Ltd | 20 | 1 |
| Agenus, Inc. | 21 | 1 |
| AiCuris GmbH &Co. KG | 22 | 1 |
| Foamix Pharmaceuticals Ltd. | 23 | 1 |
| Genocea Biosciences, Inc. | 24 | 1 |
| GenVec, Inc. | 25 | 1 |
| Immune Design Corp. | 26 | 1 |
| JN-International Medical Corporation | 27 | 1 |
| Mymetics Corporation | 28 | 1 |
| NanoBio Corporation | 29 | 1 |
| NanoViricides, Inc. | 30 | 1 |
| PaxVax, Inc. | 31 | 1 |
| Profectus BioSciences, Inc. | 32 | 1 |
| Redbiotec AG | 33 | 1 |
| Sanofi Pasteur SA | 34 | 1 |
| Shulov Innovative Science Ltd. | 35 | 1 |
| Starpharma Holdings Limited | 36 | 1 |
| Tomegavax, Inc. | 37 | 1 |
| Vaccibody AS | 38 | 1 |
| Vaxart, Inc. | 39 | 1 |
| Vical Incorporated | 40 | 1 |
| Genital Herpes Therapeutics Assessment | 41 | 9 |
| Assessment by Monotherapy Products | 41 | 1 |
| Assessment by Target | 42 | 2 |
| Assessment by Mechanism of Action | 44 | 2 |
| Assessment by Route of Administration | 46 | 2 |
| Assessment by Molecule Type | 48 | 2 |
| Drug Profiles | 50 | 40 |
| acyclovir Drug Profile | 50 | 1 |
| Aspidasept Drug Profile | 51 | 1 |
| astodrimer Drug Profile | 52 | 4 |
| G-103 Drug Profile | 56 | 1 |
| GEN-002 Drug Profile | 57 | 1 |
| GEN-003 Drug Profile | 58 | 4 |
| genital herpes (virus like particle) vaccine Drug Profile | 62 | 1 |
| genital herpes vaccine Drug Profile | 63 | 2 |
| genital herpes vaccine Drug Profile | 65 | 2 |
| genital herpes vaccine Drug Profile | 67 | 1 |
| genital herpes vaccine Drug Profile | 68 | 1 |
| genital herpes vaccine Drug Profile | 69 | 1 |
| GV-2207 Drug Profile | 70 | 1 |
| herpes simplex virus [type 1, 2] vaccine Drug Profile | 71 | 1 |
| herpes simplex virus [type 1, 2] vaccine Drug Profile | 72 | 1 |
| herpes simplex virus 2 vaccine Drug Profile | 73 | 1 |
| herpes simplex virus 2 vaccine Drug Profile | 74 | 1 |
| herpes simplex virus 2 vaccine Drug Profile | 75 | 1 |
| herpes simplex virus 2 vaccine Drug Profile | 76 | 1 |
| herpes simplex virus 2 vaccine Drug Profile | 77 | 1 |
| herpes simplex virus 2 vaccine Drug Profile | 78 | 1 |
| HSV-529 Drug Profile | 79 | 2 |
| pritelivir Drug Profile | 81 | 2 |
| Small Molecule for Genital Herpes Drug Profile | 83 | 1 |
| VCLHB-01 Drug Profile | 84 | 2 |
| VCLHM-01 Drug Profile | 86 | 2 |
| ZEP-3 Drug Profile | 88 | 2 |
| Genital Herpes Dormant Projects | 90 | 2 |
| Genital Herpes Discontinued Products | 92 | 1 |
| Genital Herpes Product Development Milestones | 93 | 13 |
| Featured News &Press Releases | 93 | 1 |
| Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits | 93 | 1 |
| Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016 | 93 | 1 |
| Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing | 94 | 1 |
| Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging | 95 | 1 |
| Feb 03, 2016: Model helps decide drug dose for clinical testing | 96 | 1 |
| Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003 | 96 | 1 |
| Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003 | 97 | 1 |
| Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine | 98 | 1 |
| Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015 | 99 | 1 |
| May 20, 2015: Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003 | 99 | 1 |
| Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences | 100 | 1 |
| Jan 07, 2015: Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN-003 for Treatment of Genital Herpes | 101 | 1 |
| Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection | 102 | 1 |
| Jun 26, 2014: Agenus Vaccine Shows Significant Reduction in Viral Burden After HerpV Generated Immune Activation | 103 | 1 |
| Nov 07, 2013: Agenus HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial | 104 | 2 |
| Appendix | 106 | 2 |
| Methodology | 106 | 1 |
| Coverage | 106 | 1 |
| Secondary Research | 106 | 1 |
| Primary Research | 106 | 1 |
| Expert Panel Validation | 106 | 1 |
| Contact Us | 106 | 1 |
| Disclaimer | 107 | 1 |